Gliclazide

StudyPopulationInterventionOutcomesResultsCommentsDesignEL
Fallucca, 199627822 young patients newly diagnosed with type 1 diabetes
Aged 12–25 years
Italy
Intervention started from the third week since the onset of the disease
Studied every 6 months for 18 months
Treatment
  1. insulin and gliclazide 160 mg/24 hours
  2. insulin and placebo
Plasma glucose
C-peptide
HbA1c
Insulin need
Insulin need was the same in the 2 groups for time 0 but thereafter it steadily decreased in the gliclazide group, becoming at 6, 12 and 18 months respectively 54%, 42% and 39% that of the placebo group, these differences were statistically significantly (p < 0.003, p < 0.001 and p < 0.001 respectively)
No statistically significant difference in the metabolic control (glycated haemoglobin and plasma glucose p > 0.05 for all time periods) between the 2 groups
The gliclazide group had statistically significantly higher C-peptide levels, which was about double those of the placebo group (p < 0.003)
No description of how randomisation took placeRCT, single blindIb

From: Evidence tables

Cover of Type 1 Diabetes
Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People.
NICE Clinical Guidelines, No. 15.2.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2004 Sep.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Women’s and Children’s Health to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.